BRCA2 and head and neck squamous cell carcinoma: The frequency of somatic mutations in BRCA1 (6%), BRCA2 (7%), ATR (4–10%) and ATM (1–16%) support the rationale for targeting components of the DNA repair pathway as druggable targets in HNSCC [203].